Добавил:
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

KAPLAN_USMLE_STEP_1_LECTURE_NOTES_2018_BIOCHEMISTRY_and_GENETICS

.pdf
Скачиваний:
24
Добавлен:
29.01.2024
Размер:
10.81 Mб
Скачать

Part II Medical Genetics

Answers

1.Answer: A. The female II-1 in this family is heterozygous for the marker (from the gel) and also has an unaffected father. Her mother is a carrier and the bottom band in the mother’s pattern is associated with the diseaseproducing allele of the factor VIII gene. All observations are consistent with II-1 being heterozygous (Xx) for the factor VIII gene. She has no symptoms, so she is not a manifesting heterozygote (choice E). She cannot be homozygous for the disease-producing allele (choice B) because her father is unaffected. Homozygosity for the normal allele (choice C) is inconsistent with the results shown on the gel. She has inherited the chromosome from her mother (bottom band) that carries the mutant factor VIII allele, but from her father she has received a chromosome carrying the normal allele. Note that her father is not affected, and the bottom band in his pattern is in linkage phase with the normal allele of the gene. This is a case where linkage phase is different in the mother and the father. Incomplete penetrance (choice D) is not a good choice because the female (II-1) does not have the disease-producing genotype. She is heterozygous for the recessive and (dominant) normal allele. One would expect from her genotype that she would be unaffected.

2.Answer: C. The blot shows the top band in the patterns of I-1 and II-2 (the proband) is associated with the disease-producing allele. Because the fetus has inherited this marker allele from the mother (II-2) and Marfan disease is dominant, the fetus will develop Marfan disease. Choices A and B are recurrence risks associated with the pedigree data. With no blot to examine, choice B, 50% risk would be correct. Choice D would be correct if the blot from the fetal DNA showed both the bottom band (must be from mother) and the top band (from the unaffected father). Choice E is incorrect because Marfan is a dominant disease with no “carrier” status.

3.Answer: E. Although II-3 has an RFLP pattern consistent with heterozygosity for the PKU allele, she has PKU. The best explanation offered is that recombination has occurred, and although she is heterozygous for the restriction site generating the RFLP pattern, she is homozygous for the mutation causing PKU. The restriction site is 10 million bp upstream from the phenylalanine hydroxylase gene so there is a minimum chance of recombination of 10%. Although this is small, it is the most likely of the options listed. The phenylalanine hydroxylase gene is not on the X chromosome (choice A). Heteroplasmy (choice B) is associated with mitochondrial pedigrees, and the phenylalanine hydroxylase gene is a nuclear one. The RFLP pattern is quite consistent with I-2 being the biologic father (choice C), and he is a known carrier of the PKU mutation because he has another affected child (II-1). If II-3’s RFLP pattern showed homozygosity for the marker (identical to II-1), and she had no symptoms, incomplete penetrance (choice D) would be a good choice.

404

Chapter 6 Genetic Diagnosis

4.Answer: C. The disease-producing allele of the gene is associated with the presence of the HindII site. Notice that both affected males show two smaller bands (75 and 40 bp). II-3, a carrier female, also has these two smaller bands in her pattern, in addition to a larger PCR product (115 bp), representing the absence of the HindII site on her normal chromosome. III-2 has only the larger PCR product (notice the density because both chromosomes yielded this product). She is homozygous for the normal allele. Choice A, carrier, would be correct if her pattern had looked like those of II-3 and III-1. All the males shown are hemizygous (choice B) for the dystrophin gene because they have only one copy. II-1 and III-3 are hemizygous for the disease-producing allele, and II-2 is hemizygous for the normal allele. No one in the family is homozygous for the diseaseproducing allele (choice D). In an X-linked pattern, this would be characteristic of a female with two copies of the disease-producing allele and is very rarely seen. III-2 is not a manifesting heterozygote (choice E) because she has no symptoms and is not a heterozygote.

5.Answer: E. The blot indicates that both parents are heterozygous for the mutant allele. Because both are phenotypically normal, the disease must be autosomal recessive. If it had been X-linked recessive, the man would be hemizygous. Thus, the chance they will have an affected child is 25% (0.25).

6.Answer: A. The affected grandfather has marker alleles DS2 and DS3. There is no information about which one is in linkage phase with his diseaseproducing huntingtin allele. On the basis of the pedigree alone, the daughter has a 25% change of inheriting the grandfather’s disease-producing huntingtin allele (choice B); however, she would like more information. Because her father (II-1) does not wish to be tested or know about his genetic status with respect to Huntington’s, it is unethical to test the daughter for the triplet repeat expansion. The results would necessarily reveal the status of her father also. By doing an indirect genetic test, one can see the daughter has inherited one of her marker alleles (DS2) from the grandfather via her father. This means she has a 50% chance of developing Huntington’s because there is a 50% chance that DS2 is a marker for the disease-producing huntingtin allele in the grandfather and a 50% chance it is not (and DS3 is). Notice the result does not reveal additional information about her father (II-1). Before her testing, he had a 50% chance of having the disease-producing huntingtin allele. His risk is still 50% with the information from the daughter’s test. However, if the father (II-1) does develop Huntington’s in the future, that will mean that the daughter has a 100% chance of having the disease also (choice D).

If her marker status had been DS1/DS1, her chances of developing Huntington’s would have been near 0 (choice E) because she did not inherit these alleles from her grandfather. One came from her grandmother (via her father) and one from her mother. This result still would not reveal additional relevant information about her father (II-1), whose risk would remain 50%.

405

Index

A

Abetalipoproteinemia, 236–237 Acetyl-CoA

alcohol to, 214 β-oxidation, 244–249

cholesterol synthesis, 232, 237 citric acid cycle, 193–195, 245 fatty acid synthesis, 224, 225, 226 fatty acids as energy storage, 164 glucose from, 211, 213

glucose to, 224–225

ketone body metabolism, 249–252 ketone body source, 168, 213, 244,

245, 249

liver synthesizing, 166, 167, 168 metabolism overview, 163, 164 postabsorptive state, 167, 214 prolonged fast, 168, 251

pyruvate carboxylase, 214, 245, 251 pyruvate dehydrogenase, 187–188, 214 regulation by, 214

well-fed state, 166

Acetyl-CoA carboxylase, 224, 225 N-acetylglutamate, 268

Acid maltase deficiency, 209–210 Ackee fruit, 248

Acrocentric chromosomes, 349 Robertsonian translocations, 349,

358–360 Actinomycin D transcription

inhibition, 34–35 Activation domain, 78

Acute intermittent porphyria, 276–277, 306

barbiturates and, 276, 277 delayed age of onset, 318

Acute myelogenous leukemia, 358 Acute myocardial infarction and

troponin, 198 Adenine, 5, 7, 9

Adeno-associated viruses (AAV), 95 Adenosine deaminase (ADA)

deficiency, 295, 296 Adenosylcobalamin, 274

S-Adenosylmethionine (SAM), 273 Adenoviruses as delivery vectors, 95 Adipose tissue

fatty acid synthesis, 224 fuels preferred by, 168

glucose transport, 176, 177 glycolysis, 181

insulin response, 169, 170, 243 metabolism overview, 169 postabsorptive state, 165, 167, 245 prolonged fast, 168, 169 triglyceride synthesis, 226 well-fed state, 165, 168

Adjacent segregation

reciprocal translocations, 356, 357 Robertsonian translocations, 359, 360

ADP accumulation and citric acid cycle, 200

ADP-ribosylation, 143–144 Aerobic glycolysis

ATP plus NADH quantities, 182 high-fructose drinks, 186 lactate levels, 180

mitochondria and oxygen, 177 muscle high-intensity short bursts, 170 NADH reoxidation, 179

oxidative phosphorylation, 179, 180 pyruvate dehydrogenase, 187–188 pyruvate kinase, 180

thiamine deficiency, 189

Age and Down syndrome, 352–353 Age-delayed onset of disease, 318 AIDS patient viral load assessment, 114 Alanine

alanine aminotransferase, 266, 267 alanine cycle, 214

conversion to acetyl-CoA, 214 as glucogenic, 212, 213 nitrogen excretion, 265, 266

Albinism, 270, 271 Alcaptonuria, 270, 271 Alcohol

extreme exercise and, 215 folate deficiency, 273, 275 hepatic steatosis, 215, 226 hyperuricemia and, 296 hypoglycemia and, 214–215 jaundice and bilirubin, 281

ketoacidosis and alcoholism, 252 metabolic energy in kcal/gm, 168

Aldolase B, 186, 187 deficiency, 186, 187

Aliphatic amino acid side chains, 120 Alkaptonuria, 270

Alleles, 303

allele frequency, 334, 336–337 allele-specific oligonucleotide probes,

104, 391–392

allelic heterogeneity, 271, 297, 314 frequency variation factors, 337–340 genetic drift, 338–339

haplotype, 384 Hardy-Weinberg equilibrium,

334–337

homologous chromosomes, 303 mutations producing new, 304 natural selection and, 337–338 polymorphism, 303–304 recombination frequencies, 384–386

Allele-specific oligonucleotide (ASO) probes, 104, 391–392

Allopurinol, 296 Allosteric enzymes, 127

α1-Antitrypsin deficiency, 62

α-Glycerol phosphate shuttle, 182, 195,

196, 197

α-Ketoglutarate dehydrogenase, 194 α-Thalassemia, 52

α-Tocopherol. See Vitamin E Alport disease, 64 Alternate segregation

reciprocal translocations, 356, 357 Robertsonian translocations, 359, 360

Amino acids activation, 44, 54, 68

amino group removal, 265–267 branch-chain amino acids, 189 codon specification, 49, 50 essential, 123

glucogenic, 211, 212, 213 hydrophobic vs. hydrophilic, 119,

120, 121 ketogenic, 211

metabolic genetic deficiencies,

269–272

metabolic postabsorptive state, 165, 167

metabolic well-fed state, 165, 166, 169

metabolism in muscle cells, 170 products of, 275

protein hydrolysis, 164 protein turnover, 122–123 structure, 119–121 thiamine deficiency, 189

407

USMLE Step 1 • Biochemistry and Medical Genetics

translation, 55–57

tRNA for translation, 43–44, 45

Aminotransferases, 266, 267, 281 Ammonium ions, 265, 266, 267, 268 Amniocentesis, 398

Anaerobic glycolysis ATP quantity, 182

fast-twitch muscle fibers, 170 high-fructose drinks, 186 hypoxia, 198

lactate dehydrogenase, 180 lactate levels, 178, 180, 198 mitochondria or oxygen lack, 177 red blood cells, 165, 177, 182–183

substrate-level phosphorylation, 180 Anemia causes, 278

pernicious anemia, 274, 275 sideroblastic anemia, 277, 278

See also Hemolytic anemia;

Megaloblastic anemia; Sickle cell disease

Anencephaly, 375 Aneuploidy, 350–355

FISH to detect, 365 nondisjunction and, 352–355

Angelman syndrome, 83, 321, 322, 361 Antibiotics

tetrahydrofolate synthesis, 292 vitamin K deficiency, 158

Anticipation, 51, 53, 58, 318–320 diseases showing, 318–320, 393

Anticoagulant therapy hypercoagulable state, 161 vitamin K and, 160

Anticodon on tRNA, 44, 54, 57 Antimycin. See Cytochrome b/c1

Antineoplastic drugs, 273, 292, 293 Antioxidant vitamins, 234

Apoproteins hypolipidemias, 236–237

lipoprotein classes and, 229, 230–233 lipoprotein metabolism, 230 lipoprotein structure, 228

Arginine, 123, 125, 275

Aromatic amino acid side chains, 120 Arsenate and glycolysis, 179 Ascorbate (vitamin C), 151

as antioxidant, 234 iron absorption, 279 scurvy, 66, 68, 151

vitamin K vs. C deficiency, 159

Asparagine, 120 Aspartame, 271, 335 Aspartate, 267, 268, 269

Aspartate aminotransferase, 267 Aspirin as uncoupler, 196, 199 Atherosclerosis, 233–234

homocystinemia, 272 hypercholesterolemia, 236

ATP

acetyl CoA carboxylase, 225 aerobic glycolysis, 179, 182 amino acid activation, 54, 68 anaerobic substrate-level

phosphorylations, 180, 182 β-oxidation, 245, 246

DNA polymerase, 20

electron transport chain, 195–196, 197–198, 245

energy of reactions, 124 glycolysis, 178, 179, 180, 181, 182 GTP equivalence, 194

metabolic postabsorptive state, 165, 167

metabolic well-fed state, 166 metabolism overview, 163, 164 as nucleotide, 6, 7

nucleotide synthesis, 289, 290 P/O ratios, 198

purine catabolism, 295

thiamine deficiency and congestive heart failure, 189

transcription, 35 translation elongation, 57

Atrial natriuretic factor (ANF), 139–140

Autocrine hormones, 135 Autosomal dominant inheritance,

305–306

diseases of, 306, 316, 318–319, 384–385

Hardy-Weinberg equation, 335, 336 incomplete penetrance, 315 recombination frequency, 384–385

Autosomal monosomies, 350 Autosomal recessive inheritance,

306–307

diseases of, 307, 319, 320, 393 Hardy-Weinberg equation, 335–336

See also Carriers in inheritance

AZT, 23

B

Bacteria. See Prokaryotes Barbiturates and porphyrias, 276, 277

Barr bodies, 82, 83

as X inactivation, 309–310 B-DNA, 9

β-Oxidation, 244–249

genetic deficiencies and, 247, 248 insulin and, 245

β-Thalassemia, 40, 53 Bile

bilirubin in, 279 cholesterol in, 231, 232, 237 lipid digestion, 224 well-fed state, 166

Bile duct occlusion, 281

Bilirubin, 279–281 Biotin, 150, 213

acetyl CoA carboxylase, 225 deficiency, 213

propionyl-CoA carboxylase, 248, 249, 270

2,3-Bisphosphoglycerate (BPG), 183 Bisphosphonates, 153

Blood urea nitrogen (BUN), 269 Blood–brain barrier

bilirubin crossing, 280, 281 fatty acids not crossing, 171, 244

Blotting techniques, 10, 103–108 Body mass index (BMI)

liability for, 371–372

obesity clinical definition, 372 obesity threshold, 372

Bordetella pertussis and ADPribosylation, 143

Brain

blood–brain barrier, 171, 244, 280, 281 glucose transport, 176, 177

as insulin-independent, 165 ketogenolysis, 249, 251

metabolic fuels preferred by, 168, 171, 189, 249

metabolic postabsorptive state, 165, 167, 244, 251

metabolic prolonged fast, 165, 168, 171, 249, 250, 251

metabolic well-fed state, 165, 166, 168 metabolism overview, 171

thiamine deficiency, 189 Branched-chain ketoacid

dehydrogenase, 189, 270, 271 deficiency, 119, 270, 271, 337

Branching enzyme, 206–207 Broad beans and favism, 217, 218

Brown adipose as uncoupler, 196, 199 Burkitt lymphoma, 358

C

Calcium and vitamin D, 152–153 cAMP (cyclic AMP)

glucagon, 142

protein kinase activation, 136, 138–139

cAMP response element binding (CREB) protein

gluconeogenesis regulation, 80–81 protein kinase activation, 137, 139

as specific transcription factor, 78, 83 Cancer

antineoplastic drugs, 273, 292, 293 delayed age of onset, 318

direct DNA sequencing, 394 DNA repair and, 25, 27–28 G protein abnormalities, 143

gene expression profiling, 107

408

genetic factors for common diseases, 376

incomplete penetrance of, 316 oncogenes, 83, 357, 358

reciprocal translocation and, 357, 358 RNA interference technology, 100 telomerase of cancer cells, 23

tumor lysis syndrome, 296 Carbamoyl phosphate synthetase

deficiency, 269, 273 pyrimidine synthesis, 290, 292 urea cycle, 268

Carbohydrates

energy in kcal/gm, 168

hydrolysis in metabolism, 164, 175 in recommended diet, 168

Carbon dioxide and fatty acid synthesis, 225

Carbon monoxide, 196, 198, 280 1-carbon units, 273–275 Cardiac muscle

amino group removal, 265, 266, 267 glycogen synthesis, 205

metabolic fuels preferred by, 168, 170, 189, 249

metabolism, 170 protein catabolism, 265

thiamine deficiency and congestive heart failure, 189

Carnitine shuttle, 244, 245, 246 Carotene. See Vitamin A Carriers in inheritance

autosomal recessive inheritance, 306, 307

genetic testing, 87, 106, 398. See also

Genetic diagnosis Hardy-Weinberg equation, 335–337 inversion carriers, 362

recurrence risk, 307 retinoblastoma incomplete

penetrance, 316 sickle cell trait, 82

translocation carriers, reciprocal, 356–357

translocation carriers, Robertsonian,

358–360

X-linked recessive, 308, 336–337 CAT-2/CPT-2. See Myopathic CAT/CPT

deficiency

Cataracts, 184, 185, 186 cDNA, 92–93, 100

expression libraries, 93, 98 probe DNA via, 100, 104 reverse transcriptase PCR, 114 for transgenic animals, 93, 111

Cell cycle

chemotherapeutic agents and, 4 eukaryotic, 4–5, 18–19

gene expression and, 4–5 genes for DNA fidelity, 27

Centimorgan (cM), 385

Central dogma of molecular biology, 3 Centromeres

cell cycle, 4, 18–19 inversions involving, 362 karyotype nomenclature, 349

Cerebrosides, 253, 254

cGMP (cyclic GMP), 139–140, 155–156 Chaperones, 59

Chargaff’s rules, 9 Chloramphenicol, 58 Cholecalciferol. See Vitamin D

Cholera toxin and diarrhea, 143

Cholesterol

blood cholesterol as LDL, 231 cell membrane structure, 164, 231

hypercholesterolemia, 236, 237, 238 hyperlipidemias, 235 hypolipidemias, 236–237 lipoprotein transport, 228, 229 synthesis, 237–238

synthesis and statins, 237, 238 Cholesterol ester transfer protein

(CETP), 233

Chorionic villus sampling, 398 Chromatids, 4, 12, 18–19 Chromatin, 11–12

gene regulation, 75–76, 83 Chromosomes, 303

abnormalities, numerical, 349–355 abnormalities, structural, 355–364 abnormality assessment, 12. See also

Genetic analysis banding, 348–349 crossover in meiosis, 52, 382 cytogenetics, 347. See also

Cytogenetics

DNA replication, 4–5, 11–12, 17–19 homologous, 303, 304, 320–322 imprinting, 320–322

karyotype, 347–349 prokaryote, 18

sex chromosomes, 303, 311. See also

X chromosomes telomeres, 22–23, 349 uniparental disomy, 321 X inactivation, 309–310

See also DNA

Chronic granulomatous disease (CGD), 218

Chronic myelogenous leukemia (CML), 114, 358

special karyotyping to detect, 365 Chylomicrons, 229, 230–231

hyperlipidemias, 235–236 hypolipidemias, 236–237

as least dense lipoprotein, 228 triglyceride transport, 229, 230

Cis regulators, 77

Index

Citrate shuttle, 195, 225, 237 Citric acid cycle, 193–195

acetyl-CoA, 193–195, 245 glutamate dehydrogenase and, 267 metabolism overview, 163, 164 pyruvate dehydrogenase, 187, 188 regulation, 200

thiamine deficiency, 189 Clastogens, 355

Cloning recombinant DNA, 88 Cobalamin. See Vitamin B12

Coding strand, 35, 36, 37 Codominant genetic expression, 82

Codons

amino acid specification, 49, 50, 68 anticodon on tRNA, 44, 54, 57 start and stop codons, 50, 68

stop from nonsense mutations, 51, 52, 304

Coefficients of relationship, 340 Coenzyme A (CoA), 188

fatty acid activation, 224, 245 Coenzyme Q, 196, 197 Collagen

defective collagen syndromes, 64, 66, 67, 68, 151, 317

posttranslational modifications, 64–67

scurvy, 66, 68, 151 Color blindness, 308

Competitive inhibitors, 126–127 statins as, 126, 238

Consanguinity, 181, 307, 340 Cooperative enzymes, 127–128 CoQ

β-oxidation, 246

electron transport chain, 197, 199 statins reducing, 238

Cori cycle, 214, 215 Cortisol

gluconeogenesis regulation, 80–81, 244

hormone-sensitive lipase activation, 243, 244

receptor binding, 144 Cotrimoxazole and tetrahydrofolate,

292

Cri-du-chat disease, 52, 361 Crigler-Najjar syndromes, 280, 281 Crossover in meiosis, 52, 382

recombination mapping, 382–386 unequal crossover, 51, 52

Cyanide and oxidative phosphorylation, 196, 198

Cyanocobalamin. See Vitamin B12

Cystathionine synthase, 270, 272 Cysteine disulfide bonds, 120 Cystic fibrosis

as autosomal recessive, 307

409

USMLE Step 1 • Biochemistry and Medical Genetics

gene replacement therapy, 97 heterozygous advantage, 338 protein folding defect, 60

Cytochrome a/a3, 196, 197 Cytochrome b5, 226 Cytochrome b/c1, 196, 197, 199 Cytochrome c, 196, 197

Cytochrome P-450, 275, 277

Cytochromes as heme proteins, 275

Cytogenetics, 347 aneuploidy, 350–355 deletions, 361 euploidy, 349–350 inversions, 362–363 isochromosomes, 364 karyotypes, 347–349 molecular, 364–365 ring chromosomes, 363 translocations, 355–360

Cytosine, 5, 7, 9 deamination repair, 25, 27

D

Debranching enzyme, 208 Deletion mutations, 361

FISH to detect, 365 imprinting and, 321, 322 large segment deletion, 51, 52 microdeletions, 361

as single-gene, 304 Y chromosome, 311

δ-Aminolevulinate dehydratase, 276 lead and, 276, 278

δ-Aminolevulinate synthase (ALA), 275, 276, 277

Denaturation

of DNA, 10, 104, 108, 109

by reactive oxygen species, 199 tertiary protein structure, 59, 120

Diabetes mellitus cataracts and, 185 ketoacidosis, 252

ketone body generation, 250 lipoprotein lipase induced by, 230,

235, 236

mature-onset diabetes of the young, 181

neonatal type 1, 181 non–insulin-dependent diabetes

mellitus, 252 triglyceride levels and, 170

Dicumarol and vitamin K, 160 DiGeorge syndrome, 361 Digestion, 164, 167, 175, 224, 229

Dihydrofolate reductase (DHFR), 292, 293

2,4-Dinitrophenol (2,4-DNP), 196, 199

Diphtheria toxins, 56, 57, 68 Diploid cells, 303, 349

Direct DNA sequencing, 394 Direct genetic diagnosis, 391–394 indirect versus, 396, 397

DNA

cDNA, 92–93

denaturation, 10, 104, 108, 109 enhancers, 76, 77

Human Genome Project, 89–92 nucleosomes, 11–12 palindromes, 89–90

protein synthesis, 36 recombinant DNA, 87–88, 100 regulatory protein binding sites, 9 repair, 21, 22, 25–27

repair and disease, 27–28 replication, 3, 17–24

replication vs. gene expression, 3–5 structure, 5–9

supercoiling, 10–11, 22 synthesis, 20–21, 24, 273, 293

DNA chips, 381, 392 DNA gyrase, 23 DNA ligase, 25–27, 93 DNA polymerase

DNA repair, 25–27

DNA synthesis, 21–22, 23, 24 DNA vs. RNA synthesis, 20–21

polymerase chain reaction, 108, 109,

112, 113

reverse transcriptase, 23

DNA-binding domain, 78 Dominant inheritance, 303

autosomal dominant, 305–306. See also Autosomal dominant inheritance

Hardy-Weinberg equation, 335, 336 incomplete penetrance, 315–316 X-linked dominant, 311–312

Dot (slot) blot, 104, 392 Down syndrome, 350 FISH to detect, 365

maternal age and, 352–353 nondisjunction and, 352–355, 360 prenatal testing, 353, 360 recurrence risk, 360 Robertsonian translocations and,

359–360 Doxorubicin. See CoQ

Dubin-Johnson syndrome, 280 Duchenne muscular dystrophy, 308

E

E. coli

diarrhea from toxin, 140, 143 recombinant proteins, 94 sepsis in galactosemia, 185 shiga-like toxin, 43

Edward syndrome, 350 nondisjunction and, 352–355

410

Ehlers-Danlos syndromes, 64, 66, 67 Electron transport chain (ETC),

195–200

ATP, 195–196, 197–198, 245 electron flow, 195, 197 energy of reaction (ΔG), 195

metabolism overview, 163, 164 reactive oxygen species, 199–200

Electrophoresis. See Gel electrophoresis

ELISA (enzyme-linked immunosorbent assay), 113–114

Elongation factor-2 (eEF-2), 56, 57

Endocrine hormones as hormones, 135 Endocytosis, 232

Endonucleases, 18

cytosine deamination repair, 27 Human Genome Project, 89–90, 93 restriction endonucleases, 89–90, 93,

100, 105, 381 thymine dimer repair, 26

xeroderma pigmentosum, 27, 28 Endoplasmic reticulum, smooth, 226,

238

See also Rough endoplasmic reticulum

Energy of activation (ΔG), 124 Energy of metabolism. See Metabolism Energy of reaction (ΔG), 124

electron transport chain, 195 rate of reaction versus, 124

Enhancers of gene expression, 76, 77 genomic vs. cDNA libraries, 93 gluconeogenesis regulation, 80–81 specific transcription factors, 78, 79

Environmental factors gene flow, 340 genetic drift, 338–339

multifactorial diseases, 371, 375 natural selection, 337–338

in nondisjunction, 352 variable expression, 314

Enzymes

cooperative enzymes, 127–128 glycogen storage diseases, 208–211 inhibitors and activators, 126–127 Lineweaver-Burk equation, 126 Michaelis-Menten equation, 124–125 protein kinases, 136–141

reaction energy vs. rate, 124 transport kinetics, 128, 176–177, 179

Epidermal growth factor, 94, 141 Epinephrine

glycogen metabolism, 206, 207, 211 hypoglycemic state, 171, 243, 244 postabsorptive state, 165 prolonged fast, 168, 169

synthesis via SAM, 273 Epithelium and vitamin A, 154

Equilibrium constant (Keq), 124 Erythrocytes. See Red blood cells Erythropoietin via recombinant DNA, 94 Ethidium bromide stain, 104

Euchromatin, 11–12 Eukaryotes

DNA polymerases, 20–21, 22 DNA replication, 18–19, 21–22, 23 DNA synthesis, 20–21, 24 mRNA production, 40–42, 45

protein synthesis inhibitors, 56, 57, 58 reverse transcriptase, 23

RNA polymerases, 34–35 rRNA into ribosomes, 43 start and stop codons, 68 telomerase, 22–23 translation, 49, 55–57, 68

Euploidy, 349–350 aneuploidy, 350–355

aneuploidy detection via FISH, 365 Event statistics, 335

LOD scores, 385–386

Ex vivo gene therapy, 94, 96

X-linked severe combined immunodeficiency, 98

Exons, 40, 41, 42 Exonucleases, 18, 20, 21

F

Fabry disease, 256

Factor VIII via recombinant DNA, 94 FADH2

β-oxidation, 245–249 citric acid cycle, 193–195

electron transport chain, 195–200 glycolysis, 182

metabolism overview, 163, 164 pyruvate dehydrogenase, 188

Familial cancer

breast cancer delayed onset, 318 breast cancer direct DNA sequencing,

394

genetic factors for common diseases, 376

incomplete penetrance, 316

See also Cancer

Familial clustering, 371, 374–375 Familial hypercholesterolemia, 235, 306 Familial lipoprotein, 235

Farnesyl pyrophosphate, 237, 238 Fasting state. See Postabsorptive

metabolic state; Prolonged fast

(starvation)

Fast-twitch muscle fibers, 170, 178, 180, 205

Fats

digestion of, 224, 229 energy in kcal/gm, 168 hydrolysis, 163, 164

postabsorptive state, 167 recommended diet, 168 storage, 166, 169, 176 well-fed state, 166

Fatty acid synthase, 224, 225–226 Fatty acids

β-oxidation, 244–249 blood–brain barrier and, 171, 244 brain indirect use of, 251

cardiac muscle fuel, 170 as energy storage, 164, 176 fat hydrolysis, 163, 164

hypoglycemia response, 213, 243–244 insulin and adipose tissue, 169, 170,

243

insulin and synthesis, 169, 224–225, 226, 244, 245

lipoprotein metabolism, 229 liver synthesizing, 166, 168, 169 muscle metabolism, 170 nomenclature, 223–224 omega-3 fatty acids, 223 oxidation, 244–249 postabsorptive state, 165, 167 prolonged fast, 168, 169 synthesis, 224–226

synthesis and pyruvate dehydrogenase, 187, 188

well-fed state, 165, 166 Fatty acyl CoA, 226

Fatty acyl-CoA dehydrogenase, 196, 246, 248

Fatty acyl-CoA synthetase, 245 Favism and fava beans, 217, 218 Febuxostat, 297

Ferrochelatase. See Heme synthase

Fluorescence in situ hybridization (FISH), 365

Fluoroquinolones, 23

Foam cells (macrophages), 233, 234 Folate (vitamin B9)

deficiency, 248, 272, 273, 275, 291, 375 homocystinemia from deficiency,

272, 275 metabolism, 274

neural tube defects and, 275, 375 pregnancy and, 150, 272, 273, 275, 375 tetrahydrofolate, 273–274

vitamin B12 deficiency versus, 275

Follicular lymphomas, 358 Founder effect, 337, 339 Fragile X syndrome, 311

anticipation in, 319 genetic testing, 107

as repeat expansion disease, 53

as X-linked dominant, 311, 312, 319 Frameshift mutations, 51, 52, 304 Friedreich’s ataxia, 53, 320

anticipation in, 319, 320

as autosomal recessive, 319, 320

Index

Fructokinase, 186

Fructose 1-P aldolase (aldolase B), 186, 187

deficiency, 186, 187 Fructose metabolism, 186–187

hereditary fructose intolerance, 186, 187

high-fructose drinks, 186 Fructose-1,6-bisphosphatase, 212, 213

G

G proteins cGMP and, 140 disease and, 143

receptor activation, 137–138 signal transduction overview, 136,

143

vision and vitamin A, 155–156 G1 phase (mitosis), 4, 11, 19

DNA repair, 25, 27 G2 phase (mitosis), 4, 19

DNA repair, 25, 27 Gain-of-function mutations, 304

Huntington disease, 318 Galactokinase, 184, 185 Galactose 1-phosphate

uridyltransferase, 185 Galactose metabolism, 184–185 Galactosemia, 185, 295, 296 Gametes, 303

as haploid, 303, 349

imprinting in gametogenesis, 320 mutation transmission, 304 nondisjunction and aneuploidy,

352–355

translocation carriers, 356–357 X inactivation, 309–310

Gangliosides, 253, 254 Gaucher disease, 255, 393

Gaussian curve for liability for disease, 371–372, 373, 375

G-banding of chromosomes, 348–349 Gel electrophoresis

blotting techniques, 103–108 polymerase chain reaction products,

110, 381, 393 sickle cell anemia, 122

Gemfibrozil, 79

Gene amplification, 83

Gene expression profiling, 107 Gene flow, 340

Gene mapping

linkage analysis, 382–386 LOD scores, 385–386

online gene and marker maps, 380 polymorphic markers for, 379–381 recombination frequencies, 384–386 restriction maps, 92, 100

411

USMLE Step 1 • Biochemistry and Medical Genetics

Gene regulation

cell differentiation in utero, 82 chromatin remodeling for, 75–76, 83 co-expression of genes, 82 enhancers, 76, 77

gluconeogenesis regulation, 80–81 promoter elements, 76, 77

protein kinases, 137 RNA interference, 99–100

transcription factors, 75–76, 77, 78–79 types of mechanisms, 83

Gene therapy cDNA for, 93, 94

gene delivery vectors, 94–98 recombinant DNA for, 93

General transcription factors, 78–79 Genes, 3, 303

for DNA repair, 27

expression vs. DNA replication, 3–5 gene flow, 340

genomic libraries, 92 imprinting, 320–322

monocistronic vs. polycistronic, 39, 45 polygenic multifactorial inheritance,

371–376

for sex determination, 311 transcription, 33, 35–36 for tumor suppression, 25

unlinked vs. linked, 382–383 for X inactivation, 309

Genetic analysis

blotting techniques, 10, 103–108 direct genetic diagnosis, 391–394,

396, 397

Down syndrome, 353, 360 gene expression profiling, 107 genetic fingerprinting via PCR,

111–113

indirect genetic diagnosis, 391, 394–397

linkage analysis, 382–386

locus heterogeneity, 316–317, 386 LOD scores, 385–386

online gene and marker maps, 380 pedigree, 305. See also Pedigrees polymerase chain reaction, 108–114 polymorphic markers, 379–381 recurrence risk, 304–305 restriction fragment length

polymorphisms, 106–107.

See also RFLPs

See also Cytogenetics

Genetic diagnosis applications of, 398 direct diagnosis, 391–394

direct vs. indirect, 396, 397 indirect diagnosis, 391, 394–397 prenatal, 398

Genetic drift, 338–339

Genetic mosaicism, 309, 351 Genetic testing. See Genetic analysis Genetics

allelic heterogeneity, 271, 297 of common diseases, 371–376 cytogenetics, 347. See also

Cytogenetics definitions, 303–305

genetic code as amino acid sequence, 3, 49, 50

heteroplasmy, 313

incomplete penetrance, 315–316 inheritance, 305–313 multifactorial inheritance, 371–376 penetrance, 311, 315–316 pleiotropy, 316

population variations, 337–340. See also Population genetics

variable expression, 314

See also Mutations; Transcription; Translation

Genetics in therapeutics cloning genes as cDNA, 92–93 gene therapy, 93, 94–98

Human Genome Project, 89–92 recombinant DNA, 87–88, 93 recombinant proteins, 88, 92, 93, 94

Genomic libraries, 92, 93, 98

cDNA (expression) libraries, 93, 98 Genotype, 303, 304

genetic mosaicism, 309, 351 genotype frequencies, 333–334 Hardy-Weinberg equilibrium, 334–337 incomplete penetrance, 315–316 penetrance, 311, 315–316

variability of expression, 314 Gilbert syndrome, 280, 281 Glucagon

cholesterol and, 237, 238

fatty acid synthesis, 224–225, 226, 244, 245

gluconeogenesis regulation, 80–81, 165, 211, 213, 244

hypoglycemic state, 171 vs. insulin, 142, 164–165

vs. insulin in gluconeogenesis, 211, 213 vs. insulin in glycogen synthesis, 206 vs. insulin in glycogenolysis, 207, 211 postabsorptive state, 165, 167 prolonged fast, 168, 169

protein kinase activation, 139

Glucocorticoid response elements (GRE), 80–81

Glucokinase, 178, 179, 181, 224 Gluconeogenesis, 211–215

alcohol and, 214–215 brain use of, 251

postabsorptive state, 165, 167, 244, 245 prolonged fast, 168, 169

412

regulation, 80–81, 165, 211, 213, 214, 244

Glucose

brain use of, 168, 171, 251 fatty acid synthesis, 224–226

gluconeogenesis regulation, 80–81, 165 glycogen as polymer of, 164

glycogen synthesis, 205–208 glycolysis, 178 insulin-independence, 165

liver regulating, 166, 167, 168, 169 muscle metabolism, 170 pancreas sensing, 176, 181 postabsorptive state, 165, 167, 211 prolonged fast, 168

transport into cells, 176–177, 181 triglyceride synthesis, 227 well-fed state, 165, 166

Glucose-6-phosphatase, 212, 213 deficiency, 209, 295, 296

Glucose-6-phosphate dehydrogenase deficiency, 200, 218, 281, 308, 338 hexose monophosphate shunt, 216–217

GLUT (glucose transporters), 176–177, 181, 182

Glutamate, 265, 266, 267 γ-aminobutyric acid (GABA), 275

Glutamate dehydrogenase, 266, 267 Glutaminase, 266, 267

Glutamine, 265, 266, 267 elevated blood glutamine, 269

Glutamine synthetase, 266, 267 Glyceraldehyde 3-phosphate

dehydrogenase, 178, 179 Glycerol 3-phosphate

gluconeogenesis, 211, 212, 213, 215 triglyceride synthesis, 226, 227, 230

Glycerol kinase, 226 , 227, 231 α-Glycerol phosphate shuttle, 182, 195,

196, 197 Glycerophospholipids, 227 Glycogen

brain levels, 171

as energy storage, 164, 170, 176, 205 glycogenolysis, 142, 207–208, 211 liver regulating, 166, 167, 168 muscle storage of, 170, 176 postabsorptive state, 165, 167 prolonged fast, 169

storage diseases, 208–211 structure, 205

synthesis, 205–208 well-fed state, 165, 166

Glycogen phosphorylase, 207–208 Glycogen synthase, 205, 206, 207 Glycogenolysis, 142, 207–208, 211

Glycolysis, 177–183

aerobic vs. anaerobic, 177, 180, 182. See also Aerobic glycolysis; Anaerobic glycolysis

brain ketone metabolization, 251 carbohydrate digestion, 175 glucose transport, 176–177, 181 high-fructose drinks, 186 pyruvate dehydrogenase, 187, 188 red blood cells, 175, 182–183

Glycosylation of proteins, 61, 62, 63 collagen posttranslational

modifications, 64, 65 serine and threonine sites, 120

Golgi apparatus

collagen posttranslational modifications, 64–65

glycosylation of proteins, 61, 62, 63, 120

Goodpasture syndrome, 64 Gout, 296

hyperuricemia and, 209, 289, 295, 296 tumor lysis syndrome and, 296

Gray baby syndrome, 58

Growth factor via recombinant DNA, 94 GTP (guanosine triphosphate)

ATP equivalence, 194 citric acid cycle, 193–195 cyclic GMP, 140

energy of reactions, 124 G proteins, 137–138, 143 as nucleotide, 7

purine catabolism, 295 RNA polymerase, 20 transcription, 35 translation, 56, 57, 68

Guanine, 5, 7, 9

Guanylate cyclase, 139–140

H

Haploid cells, 303, 349 Haplotype, 384

recombination frequency, 384–385 Hardy-Weinberg equilibrium, 334–337 HDL (high-density lipoproteins), 229,

232–233 atherosclerosis, 233–234

density among lipoproteins, 228 protective aspect, 233, 234

Heinz bodies, 218 Helix-loop/turn-helix binding

domains, 78 Heme

bilirubin, 279–281 catabolism, 279–280

iron transport and storage, 278–279 synthesis, 275–276

synthesis diseases, 276–278

Heme synthase, 276 lead and, 276, 278

Hemizygous for X chromosome, 307–308, 336–337

Hemochromatosis, 278, 314 allele-specific oligonucleotide probes,

391–392

delayed age of onset, 318 heterozygous advantage, 338 penetrance of, 315–316 variable expression of, 315–316

Hemoglobin bilirubin, 279–281

fetal vs. maternal, 183 glycolysis, 183

heme catabolism, 279–280 heme synthesis, 275–279 O2 delivery, 195

reactive oxygen species and, 218

Hemolytic anemia

bilirubin to urobilinogen, 280 glucose 6-phosphate dehydrogenase

deficiency, 218, 281, 338 pyruvate kinase deficiency, 178, 183 vitamin E deficiency, 152

Hemolytic crisis, 281 Hemophilia

missense vs. nonsense mutations, 314 as X-linked recessive, 308

Hemosiderin, 279 hemochromatosis, 278

Heparin, 160

Hepatic glycogen phosphorylase deficiency, 209, 211

Hepatic steatosis, 215, 226 Hepatitis B vaccine via recombinant

DNA, 94

Hereditary fructose intolerance, 186, 187, 295, 296

Hereditary nonpolyposis colorectal cancer, 27, 28

Hers disease, 209, 211 Heterochromatin, 11–12

X inactivation, 309 Y chromosome, 311 Heteroplasmy, 313, 314 Heterozygote, 303, 304

heterozygous carriers, 336, 337.

See also Carriers in inheritance manifesting heterozygotes, 310 recessive disease advantages, 218,

338, 340

Hexokinase, 178, 179, 181

Hexose monophosphate (HMP) shunt, 216–218

HGPRT deficiency, 295, 296–297 RFLP analysis, 397

as X-linked recessive, 308, 397 High-altitude adaptation, 183

Index

High-fructose drinks, 186 Histidine, 123, 275 Histones, 11

HIV

AZT and, 23

ELISA screening, 113 polymerase chain reaction, 108,

113–114

reverse transcriptase PCR, 114 Western blotting, 108, 113–114

HMG-CoA lyase, 250 HMG-CoA reductase, 237, 238 HMG-CoA synthase, 250

hnRNA (heterogeneous nuclear RNA), 34–35

alternative splicing, 42

eukaryote mRNA processing, 41, 42, 45 Holoproscencephaly (HPE), 82 Homeodomain proteins, 78, 82, 83 Homocysteine, 270, 272, 273 Homocystinemia, 272, 275 Homocystinuria, 270, 272 Homogentisate oxidase deficiency, 270,

271

Homologous chromosomes, 303 crossover in meiosis, 52, 382 homozygous vs. heterozygous, 303,

304 imprinting, 320–322

Homozygote, 303, 304 Hormones, 135

G proteins, 137–138, 143–144 gluconeogenesis regulation, 80 insulin receptor, 140–141

insulin vs. glucagon, 142, 164–165 lipid- vs. water-soluble, 135–136 lipid-soluble hormones, 144 protein kinases, 136–140

specific transcription factor regulation, 79

Hormone-sensitive lipase (HSL), 169, 243

diabetes mellitus untreated, 250 ketoacidosis, 252

HOX (homeobox) genes, 82 Human Genome Project, 89–92, 108 Huntington disease

anticipation in, 318–319

as autosomal dominant, 306, 319 delayed age of onset, 318 polymerase chain reaction, 110 trinucleotide repeat expansion, 53,

318, 336

Hybridization of DNA, 10, 104 Hydrogen peroxide as ROS, 199–200,

218

Hydrophilic amino acids, 119, 121 Hydrophilic hormones, 135–136

See also Water-soluble hormones

413